Combination therapy of ursodeoxycholic acid and budesonide for PBC–AIH overlap syndrome: A meta-analysis

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 567-574

  Zhang, Huawei ^a,b   Yang, Jing ^a   Zhu, Rong ^a,c   Zheng, Yuanyuan ^a   Zhou, Yuqing ^a,b   Dai, Weiqi ^a   Wang, Fan ^a   Chen, Kan ^a   Li, Jingjing ^a   Wang, Chengfen ^a   Li, Sainan ^a   Liu, Tong ^a   Abudumijiti, Huerxidan ^a   Zhou, Zheng ^a,c   Wang, Jianrong ^a,c   Lu, Wenxia ^a,c   Wang, Junshan ^a   Xia, Yujing ^a   Zhou, Yingqun ^a   Lu, Jie ^a   Guo, Chuanyong ^a   more..

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Budesonide; Combination therapy; Meta analysis; PBC AIH overlap syndrome; UDCA

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BUDESONIDE; URSODEOXYCHOLIC ACID; CHOLAGOGUE; GLUCOCORTICOID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; AUTOIMMUNE HEPATITIS; COMBINATION CHEMOTHERAPY; DEATH; DISEASE COURSE; DRUG EFFICACY; HUMAN; JAUNDICE; LIVER TRANSPLANTATION; META ANALYSIS; MONOTHERAPY; PRIMARY BILIARY CIRRHOSIS; PRIMARY BILIARY CIRRHOSIS AUTOIMMUNE HEPATITIS OVERLAP SYNDROME; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSPECIFIED SIDE EFFECT; CHI SQUARE DISTRIBUTION; COMBINATION DRUG THERAPY; HEPATITIS, AUTOIMMUNE; LIVER CIRRHOSIS, BILIARY; MORTALITY; ODDS RATIO; SYNDROME; TREATMENT OUTCOME;

BUDESONIDE; CHI-SQUARE DISTRIBUTION; CHOLAGOGUES AND CHOLERETICS; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS, BILIARY; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYNDROME; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84921532954     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S74515     Document Type: Article

References (28)

1. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology. 1998;28(2):360-365.
2. Rust C, Beuers U. Overlap syndromes among autoimmune liver disease. World J Gastroenterol. 2008;14(21):3368-3373.
3. Joshl S, Cauch-Dudek K, Wanless IR, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology. 2002;35(2):409-413.
4. Talwalkar JA, Keach JC, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol. 2002;97(5):1191-1197.
5. Neuhauser M, Bjornsson E, Treeprasertsuk S, et al. Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis. Am J Gastroenterol. 2010;105(2):345-353.
6. Csepregi A, Röcken C, Treiber G, Malfertheiner P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol. 2006;12(9):1362-1366.
7. Bakker GJ, Haan YC, Maillette de Buy Wenniger LJ, Beuers U. Sarcoidosis of the liver: to treat or not to treat? Neth J Med. 2012;70(8):349-356.
8. Delgado JS, Vodonos A, Delgado B, et al. Primary biliary cirrhosis in Southern Israel: a 20 year follow up study. Eur J Intern Med. 2012;23(8):e193-e198.
9. Muratori P, Granito A, Pappas G, et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol. 2009;104(6):1420-1425.
10. Efe C, Ozaslan E, Purnak T, et al. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmun Rev. 2012;11(5):330-334.
11. Wu CH, Wang QH, Tian GS, Xu XY, Yu YY, Wang GQ. Clinical features of the overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis: retrospective study. Chin Med J (Engl). 2006;119(3):238-241.
12. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol. 2009;51(2):237-267.
13. Wu D, Wu SM, Lu J, Zhou YQ, Xu L, Guo CY. Rifaximin versus nonabsorbable disaccharides for the treatment of hepatic encephalopathy: a meta-analysis. Gastroenterol Res Pract. 2013;2013:236963.
14. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
15. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001;135(11):982-989.
16. Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998;28(2):296-301.
17. Gunsar F, Akarca US, Ersöz G, Karasu Z, Yüce G, Batur Y. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Hepatogastroenterology. 2002;49(47):1195-1200.
18. Chazouillères O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol. 2006;44(2):400-406.
19. Heurgué A, Vitry F, Diebold MD, et al. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease. Gastroenterol Clin Biol. 2007;31(1):17-25.
20. Ozaslan E, Efe C, Akbulut S, et al. Therapy response and outcome of overlap syndromes: autoimmune hepatitis and primary biliary cirrhosis compared to autoimmune hepatitis and autoimmune cholangitis. Hepatogastroenterology. 2010;57(99-100):441-446.
21. Tanaka A, Harada K, Ebinuma H, et al. Primary biliary cirrhosis - autoimmune hepatitis overlap syndrome: a rationale for corticosteroids use based on a nation-wide retrospective study in Japan. Hepatol Res. 2011;41(9):877-886.
22. Zhu JY, Shi YQ, Han ZY, et al. [Observation on therapeutic alliance with UDCA and glucocorticoids in AIH-PBC overlap syndrome]. Zhonghua Gan Zang Bing Za Zhi. 2011;19(5):334-339. Chinese.
23. Ozaslan E, Efe C, Heurgué-Berlot A, et al. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2014;12(5):863-869.
24. Manns MP, Czaja AJ, Gorham JD, et al; American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193-2213.
25. Luxon BA. Diagnosis and treatment of autoimmune hepatitis. Gastroenterol Clin North Am. 2008;37(2):461-478, vii-viii.
26. Poupon R, Poupon RE. Treatment of primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol. 2000;14(4):615-628.
27. Yokokawa J, Saito H, Kanno Y, et al. Overlap of primary biliary cirrhosis and autoimmune hepatitis: characteristics, therapy, and long term outcomes. J Gastroenterol Hepatol. 2010;25(2):376-382.
28. Cheng P, Chen K, Xia Y, et al. Hydrogen sulfide, a potential novel drug, attenuates concanavalin A-induced hepatitis. Drug Des Devel Ther. 2014;8:1277-1286.